- Poster presentation
- Open Access
Molecular characteristic of imipenem-resistant Pseudomonas aeruginosa isolated from unrinary tract infections in Southern Poland
© Pobiega et al; licensee BioMed Central Ltd. 2015
Published: 16 June 2015
Carbapenem-resistant Pseudomonas aeruginosa (PAR) has become a serious health problem worldwide. It is essential to understand its epidemiology as it may help to control the antibiotic resistance.
To analyze the molecular characteristics of carbapenem-resistant PAR in urinary tract infections in Southern Poland.
Antimicrobial susceptibility testing was performed. Metallo-beta-lactamases were detected. Multidrug-resistant (MDR) was non-susceptible to one antimicrobial in ≥3 antimicrobial classes. Extensively-drug resistant strain (XDR) was susceptible to ≤2 antimicrobial classes. MLST was performed (Curran et al ,2004).
The median (Q1;Q3) age was 60 years (54;69), 33.3% were females. Among 183 urine samples contained P. aeruginosa, 21 imipenem-non-susceptible strains were included for further analysis. MIC50 for imipenem was 12.0 mg/l. Eighteen strains (86.0%) were resistant to meropenem (MIC50=8.0 mg/l). Sixteen strains (76.0%) were resistant to doripenem. Based on the EDTA-assay, 9 (42.8%) MBL-positive isolates were identified. VIM-2 was present in three isolates. No isolates with SPM nor IMP, SIM, GIM were detected. Three (14.2%) isolates were classified as MDR, 8 as XDR (38%). MDR/XDR strains were found more often among polimycrobial infections than monomicrobial (p=0.042, OR=0.093, 95% CI 0.0085-1.00). Eight XDR strains were designated to MLST typing scheme. Four strains belonged to ST235, two strains to ST 260. The remaining two strains belonged to ST654 o ST234, respectively.
This study indicated the emergence of MDR and XDR strains producing MBL. A high prevalence of imipenem-resistant strains and MBL is a critical problem and a therapeutic challenge for clinicians. Continuous surveillance is necessary to detect the presence of MBL-producing strains. No 2012/05/N/NZ7/00786.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.